Looks at adults with high-risk early bladder cancer after BCG treatment in Korea
Studies patient care and outcomes in adults with high-risk bladder cancer after BCG.
Plain-language title generated from the registry record
Registry title: A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in Korea
Key facts
- Where
- Suwon, South KoreaSee the site
Where in South Korea
- Sungkyunkwan University Research and Business FoundationSuwon, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Janssen Korea, Ltd., Korea
- Trial code
- NCT07735793
- Record updated
- 9 November 2026
- Original description
The purpose of this study is to assess participant's overall well-being and the extent to which medical services are used by participants with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who have received Bacillus Calmette-Guérin (BCG) therapy. HR-NMIBC is a type of bladder cancer in which cancer is confined to the inner lining of the bladder and has a high risk of returning or becoming more serious. BCG therapy is a treatment administered directly into the bladder to help prevent the cancer from returning or progressing.Read full original descriptionShow less
A Real-world Study to Describe the Patient Journey, Treatment Patterns, and Outcomes of Patients With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in Korea Using HIRA Claims Data
The purpose of this study is to assess participant's overall well-being and the extent to which medical services are used by participants with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who have received Bacillus Calmette-Guérin (BCG) therapy. HR-NMIBC is a type of bladder cancer in which cancer is confined to the inner lining of the bladder and has a high risk of returning or becoming more serious. BCG therapy is a treatment administered directly into the bladder to help prevent the cancer from returning or progressing.
Inclusion: Confirmed diagnosis of bladder cancer (BC) based on International Classification of Diseases, 10th Revision (ICD-10) codes (C67 or D090) and cancer-specific insurance code V193 within the patient identification period of September 1, 2015, to August 31, 2024; Two outpatient or one inpatient visit anytime during the study period for bladder cancer; Received intravesical Bacillus Calmette-Guérin (BCG) following the qualifying transurethral resection of bladder tumor (TURBT). The date of first BCG instillation serves as the index date; No evidence of bladder cancer diagnosis, intravesical chemotherapy, or BCG in the 5-year look-back period prior to the qualifying TURBT, to ensure an incident BC definition.
Exclusion: Evidence of metastatic disease based on confirmed diagnosis (ICD-10: C77-C80) on or before index TURBT, or within 30 days after the index TURBT; Evidence of confirmed cancer diagnosis other than bladder cancer (ICD-10: C00-C76, C81-C97, excluding C67) on or before the index TURBT; Evidence of systemic treatments or radical cystectomy within 30 days after index TURBT; Less than 12 months of potential follow-up to the data cutoff after the index date (including patients with a claims-inactivity-based death proxy within 12 months from the index date).